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Abstract
Background: A pilot study revealed a relationship between the results of flow mediated skin fluores-
cence (FMSF) and of ECG-Holter-based estimated apnea/hypopnea index (eAHI) in asymptomatic 
individuals. The aim of this study was to test whether the results of FMSF show a relationship with the 
eAHI in patients with coronary artery disease or aortic stenosis. 
Methods: Twenty-one patients (12 coronary disease, 9 aortic stenosis) and 37 healthy volunteers were 
included. FMSF was assessed before, during and after the pressure occlusion of the brachial artery, us-
ing a prototype device allowing the quantification of skin fluorescence. The values of FMSF expressed as 
baseline (BASE), maximum (MAX), and minimum (MIN) were analyzed. The percentages of ischemic 
response (IR) and hyperemic response (HR) were calculated. The eAHI was assessed from night ECG-
Holter recordings. Differences between the groups and the relationships between the parameters were 
analyzed statistically.
Results: Mean ± standard deviation of BASE, MAX, MIN and IR were not significantly different 
in both groups (p > 0.05). HR was significantly lower in cardiac patients (14.7 ± 7.5 vs. 11.8 ± 5.1;  
p = 0.048), whose eAHI was significantly higher (11.0 ± 7.4 vs. 36.3 ± 16.5; p < 0.01). Negative cor-
relation for MAX and eAHI was found in volunteers and patients: r = –0.38, p = 0.02 and r = –0.47, 
p = 0.03, respectively. In volunteers, HR had a negative correlation with eAHI: r = –0.34, p = 0.04.
Conclusions: This pioneer study confirms that FMSF can be used to detect the negative correlation be-
tween MAX fluorescence and eAHI not only among healthy volunteers, but also among cardiac patients 
with coronary artery disease or aortic stenosis. (Cardiol J)
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Introduction
Sleep disordered breathing has significant 
medical implications [1]. A reliable noninvasive 
method would be valuable for the screening of this 
condition in ambulatory patients. A pilot study with 
healthy volunteers revealed a promising potential 
for the assessment of flow mediated skin fluores-
cence (FMSF) in the selection of individuals with 
episodes of obstructive apnea during sleep [2]. 
FMSF is a method of assessing the redox balance 
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nocturnal episodes of hypoxia caused by short 
periods of cessation of breathing can affect mito-
chondrial metabolism of the most superficial and 
distal organ such as skin — not only in healthy in-
dividuals, but also in cardiac patients, in whom the 
prevalence of obstructive sleep apnea is alarmingly 
high. The source of fluorescence (light of frequency 
340 nm) in this pilot study were the mitochondrial 
molecules of NADH — a reduced form of NAD+ 
(nicotinamide adenine dinucleotide) — after ab-
sorption of light energy emitted by the device 
Angiotester (Angionica Ltd., Lodz, Poland) [4]. 
The changes of the mitochondrial concentration of 
NADH are a consequence of hypoxia [5].
The aim of this study was to assess the rela-
tionship between the FMSF parameters and the 
values of the estimated apnea/hypopnea index 
(eAHI) in a group of healthy volunteers and cardiac 
patients with aortic stenosis or coronary artery 
disease (CAD). 
Methods
Thirty-seven healthy individuals were en-
rolled into the study. The inclusion criteria were:
 — age 18–40 years;
 — the absence of any treated or diagnosed chron-
ic diseases;
 — no antibiotics, pain relievers, or vaccinations 
during the prior 2 weeks;
 — signing a written consent to participate in the 
study.
Twenty-one cardiac patients hospitalized at 
the Department of Cardiology at the Medical Uni-
versity of Lodz were included, using the following 
criteria:
 — age > 40 years;
 — diagnosis of CAD confirmed in coronary 
angiography showing stenoses > 70% or 
aortic stenosis with transaortic mean gradient 
≥ 40 mmHg;
 — completed treatment — surgical or transvascular;
 — an obtained written consent for participation.
Patients with arrhythmia, after the implantation 
of devices for electrotherapy, with diagnosed sleep 
apnea syndrome or those reporting spontaneous 
symptoms suggesting sleep apnea were excluded.
All the participants signed a written consent 
before enrollment into the study. The protocol of 
the study was approved by the Local Ethics Com-
mittee at the Medical University of Lodz and was 
concordant with the Declaration of Helsinki. 
Flow mediated skin fluorescence was meas-
ured on the forearm skin after 15-minute acclima-
tization in a temperature-controlled room (20 ± 
± 1°C). First, the basic FMSF was measured for at 
least 2 minutes, followed by a measurement during 
a 100-second period of brachial artery occlusion and 
then again at least a 3-minute measurement was 
started. The flow of the blood in the left brachial 
artery was occluded by a cuff inflated around the 
arm up to 50 mmHg above systolic blood pressure. 
The following parameters were measured: base-
line fluorescence (BASE), maximum fluorescence 
(MAX) observed during occlusion, minimum fluo-
rescence (MIN) after cuff release, and the following 
parameters were calculated: ischemic response 
(IR) defined as percentage difference between 
MAX and BASE (an increase in fluorescence in-
tensity during occlusion), and hyperemic response 
(HR) defined as percentage difference between 
BASE and MIN (a decrease in intensity after the 
cuff release). Sample protocols of measurements 
performed in a healthy volunteer and in a cardiac 
patient are shown in Figures 1 and 2, respectively.
Coronary catheterization was performed ac-
cording to the standard protocol using the INNOVA 
2000 angiography system (General Electric). Two-
-dimensional echocardiography was performed by 
means of the (ViVid 7 device, GE), with the probe 
emitting ultrawaves of 2.5–4 MHz frequency ac-
cording to the guidelines of the Working Group on 
Echocardiography of the Polish Cardiac Society. 
All patients and volunteers underwent a 24-hour 
electrocardiogram (ECG) Holter monitoring 
(Pathfinder 700, DelMar Reynolds, Hertford, UK). 
A three-channel recorder Lifecard CF was used. It 
was followed by further analysis with the Pathfinder 
700 software and evaluation of the eAHI with Life-
screen Apnea (Spacelabs Healthcare, Issaquah WA, 
USA). An apneic event triggers the autonomic nerv-
ous system activation, which results in a specific 
sinus heart rhythm modulation. Lifescreen Apnea 
is a screening tool which calculates the probability 
of apneic events on the basis of changes in the beat-
to-beat intervals and the ECG-derived respiration 
signal. A detailed description of the method was 
given by de Chazal et al. [6].
A statistical analysis of mutual relationships 
between the eAHI and the parameters obtained 
from FMSF was performed using the Student t-test 
and correlation co-efficient with p value < 0.05 
regarded as significant.
Results
In the group of healthy volunteers there were 
5 (13.5%) cases of the eAHI above 15, whereas 
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Figure 1. A sample protocol of measurement of flow mediated skin fluorescence in a healthy volunteer — baseline 
fluorescence (BASE) — 316200 arbitrary units, maximum fluorescence (MAX) — 364100, arbitrary units, minimum 
fluorescence (MIN) — 262400 arbitrary units, ischemic response — 15.1% and hyperemic response — 17.0%; Przed 
— the beginning; Koniec — the end.
Figure 2. A sample protocol of measurement of flow mediated skin fluorescence in a cardiac patient — baseline 
fluorescence (BASE) — 286500 arbitrary units, maximum fluorescence (MAX) — 299400 arbitrary units, minimum 
fluorescence (MIN) — 261000 arbitrary units, ischemic response — 4.5% and hyperemic response — 8.9%; Przed — 
the beginning; Koniec — the end.
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among cardiac patients there were 18 (85.7%) 
such cases.
The comparison of characteristics of volun-
teers and cardiac patients is presented in Table 1. 
All the cardiac patients received beta-blockers, 
angiotensin-converting enzyme inhibitors and 
statins, 12 (57.1%) patients were on antidiabetic 
medication. 
No significant differences were found between 
the values of basic, maximal, and minimal fluores-
cence, and in the IR between the cardiac patients 
and volunteers; however, HR was significantly 
higher in the volunteers — 14.7 ± 7.5 vs. 11.8 ± 5.1 
(p = 0.048). The detailed data are presented in Table 2. 
Interestingly, despite similar average fluorescence 
values between the two investigated groups, 
significant negative correlation coefficients were 
found between the values of maximal fluorescence 
and the eAHI in both groups. Additionally, signifi-
cant negative correlation was found for HR and the 
eAHI in healthy volunteers (Table 3). 
Discussion
The main finding of the present study is that 
the severity of sleep apnea assessed by means of 
the eAHI derived from 24-hour Holter monitoring 
is correlated with noninvasive measurements of 
redox parameters obtained in vivo in a simple rapid 
test, i.e., FMSF. This was observed both in healthy 
volunteers and in cardiac patients. 
Table 3. The correlations between flow mediated 
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Table 2. Results of flow mediated skin fluorescence measurements.
Variable Healthy volunteers  
(n = 37)






360.2 ± 122.9 384.2 ± 182.9 0.505
Maximal fluorescence 
[×103 arbitrary units]
394.3 ± 140.1 395.1 ± 206.1 0.986
Minimal florescence 
[×103 arbitrary units]
300.5 ± 103.4 336.3 ± 206.0 0.240
Ischemic response [%] 2.4 ± 9.8 0.15 ± 4.9 0.176
Hyperemic response [%] 14.7 ± 7.5 11.8 ± 5.1 0.048
Table 1. The clinical characteristics of the studied groups.
Variable Healthy volunteers  
(n = 37)




Age [years] 32.9 ± 5.2 65.9 ± 8.8 < 0.001
Sex, female 12 [32.4] 7 [33.3] 1.0
Body mass index 26.13 ± 2.9 27.6 ± 4.1 0.065
Systolic blood pressure [mmHg] 125.62 ± 9.38 131.12 ± 16.04 0.002
Diastolic blood pressure [mmHg] 78.97 ± 6.72 80.57 ± 12.48 < 0.001
Fasting glucose [mg/dL] 89.56 ± 8.06 108.92 ± 32.5 < 0.001
LDL-cholesterol [mg/dL] 109.14 ± 31.8 99.1 ± 38.7 0.238
Hemoglobin concentration [g/L] 15.98 ± 1.17 13.71 ± 1.54 < 0.001
Estimated apnea/hypopnea index 11.0 ± 7.4 36.3 ± 16.5 < 0.001
Left ventricular ejection fraction [%] 62.29 ± 2.71 51.07 ± 8.21 < 0.001
Peak aortic jet velocity [m/s] 1.26 ± 0.11 2.34 ± 1.51 < 0.001
LDL — low-density lipoprotein
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This finding is especially practical in the con-
text of very high prevalence of abnormal eAHI in 
cardiac patients, in the absence of self-reported 
sleepiness or the presence of risk factors for 
sleep-disordered breathing. This observation is 
concordant with the results of previous studies by 
Ben Ahmed et al. [7] and by Mehra et al. [8], and 
it underlines a strong need for reliable and easy 
tools for sleep apnea screening. 
The reference method — polysomnography 
— is a costly procedure, time-consuming and 
less available, and therefore it cannot be used as 
a screening test. Therefore, Holter monitoring is 
often proposed for first-step diagnostics of sleep 
apnea. Recent publications confirm the reliability 
of a simpler diagnosis of obstructive respiratory 
disorders on the basis of 24-hour Holter monitor-
ing by means of the Lifescreen Apnea software 
making use of eAHI in various groups of patients 
for screening purposes. This approach was used 
in our study and it was observed previously that 
the cut-off value of eAHI set at 17 was optimal 
for the differentiation between patients with or 
without sleep-related breathing disorders [9, 10]. 
The existing evidence confirms the repeatability 
of the results of Holter-based eAHI derived from 
two consecutive nights on the basis of 48-hour ECG 
monitoring [11]. The critical advantage of FMSF 
over 24-hour Holter monitoring as a screening tool 
for sleep apnea is the much shorter duration of the 
test, which takes only 25 minutes.
The application of FMSF for the detection of 
abnormal microvascular function in healthy con-
trols and patients with stable CAD was already 
described by Hellmann et al. [12]. Those authors 
reported both the excellent reproducibility of 
FMSF examination performed day by day and 
a significantly lower IR and HR when cardiac pa-
tients were compared with healthy volunteers. The 
same relationship was found in the present groups, 
but the difference was significant only for HR. The 
next study of that team, published by Tarnawska et 
al. [13], emphasizes a significant inverse correla-
tion of HR with the blood concentration of ADMA 
(asymmetric dimethyl arginine — endogenous 
competitive inhibitor of nitric oxide synthase), and 
of IR with the concentration of endothelin-1 — va-
soconstrictor and mitogen produced in response to 
hypoxia and vascular wall stress [13]. Neverthe-
less, the problem of night periods of hypoxia due to 
sleep apnea was not investigated in that previous 
study and the current report seems to be the first 
in this field of investigations. 
The potential impact of night periods of hy-
poxia on the status of mitochondria on the follow-
ing morning was described by two independent 
teams — Lacedonia et al. [14] and Kim et al. [15] 
— who found that people with obstructive sleep 
apnea have a higher concentration of damaged mi-
tochondrial DNA than people without this disease. 
Since mitochondria are the only organelle where 
NADH — the source of fluorescence — is present, 
and since they have limited DNA repair capacity, 
impaired mitochondrial function could explain the 
linkage between sleep apnea and the lower values 
of HR observed with FMSF in the individuals par-
ticipating in the present study.  
The lack of polysomnography to diagnose 
sleep apnea and the relatively small groups partici-
pating in the study should be regarded as the main 
limitation of this study. Further investigations of 
this phenomenon on a larger sample of participants 
and with the use of methods directly assessing 
sleep apnea should be performed. 
Conclusions
This pioneer study confirmed in a relatively 
small study group that a noninvasive test — FMSF 
can be used to detect a negative correlation be-
tween maximum FMSF and the eAHI not only 
among healthy volunteers, but also among cardiac 
patients with CAD or aortic stenosis.
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